Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
OR

NASDAQ · ORGO

Organogenesis Holdings Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$0.76

Down-$0.01 (-1.64%)

Updated Nov 3, 2026, 8:06 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
607.66M
P/E ratio
-69.15
Dividend yield
0.00%
52-week range
$0.73 – $7.08
Volume
2.32M
Avg. volume
1.55M

Price performance · ORGO

ORGO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ORGO closed at $0.76 after 21 trading sessions, down 41.43% for the selected period.

Last close
$0.76
Period change
-41.43%
Period low
$0.76
Period high
$1.34
Daily close
View OHLC price history
ORGO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$0.78$0.80$0.73$0.75552.32M
Oct 30, 2026$0.8046$0.8203$0.7623$0.7681760.31K
Oct 29, 2026$0.82$0.8634$0.8112$0.81891.01M
Oct 28, 2026$0.89$0.9199$0.8091$0.82471.8M
Oct 27, 2026$0.935$0.9477$0.8931$0.9024877.18K
Oct 26, 2026$0.9938$1.01$0.9311$0.9354698.27K
Oct 23, 2026$1.02$1.03$0.933$0.99321.34M
Oct 22, 2026$0.9852$1.045$0.9813$1.03723.61K
Oct 21, 2026$1.04$1.06$0.9604$0.99131.15M
Oct 20, 2026$1.03$1.105$1.00$1.021.87M
Oct 19, 2026$1.01$1.05$0.9286$1.02989.11K
Oct 16, 2026$1.12$1.13$0.9901$0.99971.27M
Oct 15, 2026$1.14$1.145$1.10$1.11782.69K
Oct 14, 2026$1.19$1.20$1.13$1.14652.85K
Oct 13, 2026$1.24$1.24$1.195$1.21706.93K
Oct 12, 2026$1.28$1.28$1.22$1.23506.69K
Oct 9, 2026$1.28$1.31$1.27$1.29402.07K
Oct 8, 2026$1.29$1.31$1.25$1.28750.04K
Oct 7, 2026$1.34$1.39$1.30$1.32772.03K
Oct 6, 2026$1.30$1.35$1.29$1.34608.73K
Oct 5, 2026$1.32$1.338$1.275$1.291.83M

Latest ORGO news

The latest Smart Investors Daily articles mentioning ORGO.

Stock researchCompany · Overview

ORGO research

Overview

Company profile and research snapshot.

Company profile

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ORGO recent ratings
DateFirmRatingTarget
Aug 7, 2026Truist SecuritiesHold—
May 28, 2026Truist SecuritiesHold—
Mar 26, 2026BTIGBuy—
Feb 27, 2026BTIGBuy—
Dec 26, 2025BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 12, 2026

Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of previously released results from PREPARE1, a prospective, multicenter, randomized controlled trial (RCT) evaluating PuraPly®AM (PCMP) plus standard of care (SoC) compared to SoC alone in hard-to-heal diabetic foot ulcers (DFUs). The

Yahoo · Oct 12, 2026

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026

CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that third quarter of fiscal year 2026 financial results will be reported after the market closes on Thursday, November 5th. Management will host a conference call at

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By